Answers are grounded in this paper and cite their sources.
Betaxolol (BTX) is a cardioselective β 1-adrenergic receptor antagonist used in the management of hypertension and chronic open-angle glaucoma, for which reliable analytical determination is important to support safe and effective therapeutic use. In this study, silver nanostructure with prisms morphology (AgNPrs) were introduced as an optical nanoplatform for the development of simple and portable colorimetric assays for BTX which confirmed by UV-Vis method. The interaction of BTX with AgNPrs was evidenced by a pronounced change in electrophoretic mobility from 3.25 to 8.90 μm s −1 V −1 cm, indicating modification of the nanoparticle surface upon analyte binding. This optical response was subsequently integrated into two microscale portable colorimetric substrates ( µ PCSs) fabricated on Parafilm and poly(methyl methacrylate) (PMMA). Both platforms enabled single-drop BTX analysis, with smartphone-based image acquisition and digital color analysis providing a convenient alternative to conventional instrumentation. The developed micro-scale portable colorimetric substrates ( µ PCSs) afforded low limits of quantification of 2 and 10 µM for BTX in standard solutions and human blood plasma, respectively. The analytical response was successfully extended to real-sample analysis, demonstrating the applicability of the platforms to biological matrices. Overall, the combination of AgNPr-based optical transduction, low-volume microscale analysis, and smartphone-assisted digital readout provides a simple, cost-effective, and portable strategy for BTX determination. These findings demonstrate the potential of AgNPr-decorated µ PCSs as accessible analytical platforms for rapid on-site colorimetric analysis of pharmaceutical compounds.
No takes yet. Share an insight, caveat, or question.
Behyar et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: